News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1Macro headwinds test Bitcoin price as $70K crumbles amid US market volatility2Trump filling Democratic seats at SEC, CFTC could advance crypto bill talks, TD Cowen says3Bitcoin price ignores $168M Strategy buy, and falls as Iran tensions escalate
Kenvue: Fourth Quarter Financial Highlights
101 finance·2026/02/17 22:15
Pump.fun tackles ‘token deployers who don’t deserve the fees’ with cashback feature
Cryptopolitan·2026/02/17 22:12
Toll Brothers (NYSE:TOL) Surprises With Strong Q4 CY2025
Finviz·2026/02/17 22:03
Japan Plans $36 Billion Investment in US Initiatives as Part of Trump Agreement
101 finance·2026/02/17 22:03
Pump.fun tackles ‘token deployers who don’t deserve the fees’ with cashback feature
Cryptopolitan·2026/02/17 22:03
Bel Fuse: Fourth Quarter Earnings Overview
101 finance·2026/02/17 21:57
Genco (NYSE:GNK) Beats Expectations in Strong Q4 CY2025
Finviz·2026/02/17 21:54
Flash
22:17
Berkshire Hathaway built a position in The New York Times in Q4, reduced holdings in Amazon and Bank of AmericaGlonghui, February 18th｜The 13F report shows that Berkshire Hathaway established a new position in The New York Times in the fourth quarter. Increased holdings in Chubb, Chevron, Domino's Pizza, and Lamar. Reduced holdings in Amazon, Bank of America, DaVita, Pool Corp., and Aon Plc. Major holdings include Apple, American Express, Bank of America, Coca-Cola, and Chevron.
22:00
Canada S&P/TSX Composite Index closed down 0.54% at 32,896.55 points; Small Cap Index closed down 1.28% at 1,334.87 points.The Mexico Composite Index closed down 0.28%. The Brazil Bovespa Index closed down 0.30%.
22:00
AC Immune SA announces voluntary suspension of recruitment for its Phase II clinical trial (code-named Retain) for Alzheimer's disease treatmentThe company emphasized that this decision is not based on any new security issues or adverse events, but rather stems from internal strategic considerations. This suspension is a temporary measure aimed at optimizing trial processes and resource allocation. AC Immune SA stated that it will decide when to resume patient recruitment based on subsequent evaluation results and is committed to promptly informing investors and regulatory authorities of any progress.
News